PPAR-α and PPAR-γ agonists for type 2 diabetes

被引：31
作者：
Charbonnel, Bernard [1 ]
机构：
[1] Univ Nantes, Inst Thorax, Dept Endocrinol & Diabet, F-44000 Nantes, France
来源：
LANCET | 2009年 / 374卷 / 9684期
关键词：
EVENTS; FENOFIBRATE; MELLITUS; GLUCOSE; DEATH;
D O I：
10.1016/S0140-6736(09)61040-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：96 / 98
页数：3
相关论文
共 15 条
[1]   PPAR dual agonists: Are they opening Pandora's box? [J].
Balakumar, Pitchal ;
Rose, Madhankumar ;
Ganti, Subrahmanya S. ;
Krishan, Pawan ;
Singh, Manjeet .
PHARMACOLOGICAL RESEARCH, 2007, 56 (02) :91-98
[2]   Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes [J].
Benardeau, Agnes ;
Benz, Joerg ;
Binggeli, Alfred ;
Blum, Denise ;
Boehringer, Markus ;
Grether, Uwe ;
Hilpert, Hans ;
Kuhn, Bernd ;
Maerki, Hans Peter ;
Meyer, Markus ;
Puentener, Kurt ;
Raab, Susanne ;
Ruf, Armin ;
Schlatter, Daniel ;
Mohr, Peter .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (09) :2468-2473
[3]   Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].
Dormandy, JA ;
Charbonnel, B ;
Eckland, DJA ;
Erdmann, E ;
Massi-Benedetti, M ;
Kmoules, IK ;
Skene, AM ;
Tan, MH ;
Lefébvre, PJ ;
Murray, GD ;
Standl, E ;
Wilcox, RG ;
Wlhelmsen, L ;
Betteridge, J ;
Birkeland, K ;
Golay, A ;
Heine, RJ ;
Korányi, L ;
Laakso, M ;
Mokán, M ;
Norkus, A ;
Pirags, V ;
Podar, T ;
Scheen, A ;
Scherbaum, W ;
Schernthaner, G ;
Schmitz, O ;
Skrha, J ;
Smith, U ;
Taton, J .
LANCET, 2005, 366 (9493) :1279-1289
[4]   PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome [J].
Fievet, Catherine ;
Fruchart, Jean-Charles ;
Staels, Bart .
CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (06) :606-614
[5]   Effect of a multifactorial intervention on mortality in type 2 diabetes [J].
Gaede, Peter ;
Lund-Andersen, Henrik ;
Parving, Hans-Henrik ;
Pedersen, Oluf .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (06) :580-591
[6]   Molecular basis of selective PPARγ modulation for the treatment of type 2 diabetes [J].
Gelman, Laurent ;
Feige, Jerome N. ;
Desvergne, Beatrice .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2007, 1771 (08) :1094-1107
[7]   Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study [J].
Henry, Robert R. ;
Lincoff, A. Michael ;
Mudaliar, Sunder ;
Rabbia, Minchael ;
Chognot, Cathy ;
Herz, Matthias .
LANCET, 2009, 374 (9684) :126-135
[8]   Glucose Control in Type 2 Diabetes Still Worthwhile and Worth Pursuing [J].
Kahn, Steven E. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (15) :1590-1592
[9]   Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial [J].
Keech, A ;
Simes, RJ ;
Barter, P ;
Best, J ;
Scott, R ;
Taskinen, MR ;
Forder, P ;
Pillai, A ;
Davis, T ;
Glasziou, P ;
Drury, P ;
Kesäniemi, YA ;
Sullivan, D ;
Hunt, D ;
Colman, P ;
d'Emden, M ;
Whiting, M ;
Ehnholm, C ;
Laakso, M .
LANCET, 2005, 366 (9500) :1849-1861
[10]   Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial [J].
Keech, A. C. ;
Mitchell, P. ;
Summonen, P. A. ;
O'Day, J. ;
Davis, T. M. E. ;
Moffitt, M. S. ;
Taskinen, M. R. ;
Simes, R. J. ;
Tse, D. ;
Williamson, E. ;
Merrifield, A. ;
Laatikainen, L. T. ;
d'Emden, M. C. ;
Crimet, D. C. ;
O'Connell, R. L. ;
Colman, P. G. .
LANCET, 2007, 370 (9600) :1687-1697
12